O	0	7	Patient
O	7	8	-
O	8	16	reported
O	17	25	outcomes
O	26	28	in
O	29	34	women
O	35	39	with
O	40	46	breast
O	47	53	cancer
O	54	62	enrolled
O	63	65	in
O	66	67	a
O	68	72	dual
O	72	73	-
O	73	79	center
O	79	80	,
O	81	87	double
O	87	88	-
O	88	93	blind
O	93	94	,
O	95	105	randomized
O	106	116	controlled
O	117	122	trial
O	123	132	assessing
O	133	136	the
O	137	143	effect
O	144	146	of
B-intervention	147	158	acupuncture
O	159	161	in
O	162	170	reducing
B-condition	171	180	aromatase
I-condition	181	190	inhibitor
I-condition	190	191	-
I-condition	191	198	induced
I-condition	199	214	musculoskeletal
I-condition	215	223	symptoms
O	223	224	.

O	225	234	Aromatase
O	235	245	inhibitors
O	246	247	(
O	247	250	AIs
O	250	251	)
O	252	256	have
O	257	261	been
O	262	272	associated
O	273	277	with
O	278	288	decrements
O	289	291	in
O	292	299	patient
O	299	300	-
O	300	308	reported
O	309	317	outcomes
O	318	319	(
O	319	323	PROs
O	323	324	)
O	324	325	.

O	326	329	The
O	330	339	objective
O	340	342	of
O	343	347	this
O	348	353	study
O	354	357	was
O	358	360	to
O	361	367	assess
O	368	375	whether
O	376	380	real
O	381	392	acupuncture
O	393	394	(
O	394	396	RA
O	396	397	)
O	397	398	,
O	399	407	compared
O	408	412	with
O	413	417	sham
O	418	429	acupuncture
O	430	431	(
O	431	433	SA
O	433	434	)
O	434	435	,
O	436	444	improves
O	445	449	PROs
O	450	452	in
O	453	461	patients
O	462	466	with
O	467	473	breast
O	474	480	cancer
O	481	484	who
O	485	488	are
O	489	498	receiving
O	499	501	an
O	502	510	adjuvant
O	511	513	AI
O	513	514	.

B-eligibility	515	529	Postmenopausal
I-eligibility	530	535	women
I-eligibility	536	540	with
I-eligibility	541	542	a
I-eligibility	543	548	stage
I-eligibility	549	550	0
I-eligibility	551	558	through
I-eligibility	559	562	III
I-eligibility	563	569	breast
I-eligibility	570	576	cancer
I-eligibility	577	580	who
I-eligibility	581	589	received
I-eligibility	590	592	an
I-eligibility	593	595	AI
I-eligibility	596	599	and
I-eligibility	600	603	had
I-eligibility	604	613	treatment
I-eligibility	613	614	-
I-eligibility	614	624	associated
I-eligibility	625	640	musculoskeletal
I-eligibility	641	649	symptoms
O	650	654	were
O	655	665	randomized
O	666	668	to
O	669	676	receive
O	677	678	8
O	679	685	weekly
O	686	688	RA
O	689	695	versus
O	696	698	SA
O	699	701	in
O	702	703	a
O	704	708	dual
O	708	709	-
O	709	715	center
O	715	716	,
O	717	727	randomized
O	728	738	controlled
O	739	744	trial
O	744	745	.

O	746	749	The
O	750	758	National
O	759	767	Surgical
O	768	776	Adjuvant
O	777	783	Breast
O	784	787	and
O	788	793	Bowel
O	794	801	Project
O	802	803	(
O	803	808	NSABP
O	808	809	)
O	810	820	menopausal
O	821	829	symptoms
O	830	843	questionnaire
O	843	844	,
O	845	848	the
O	849	855	Center
O	856	859	for
O	860	875	Epidemiological
O	876	883	Studies
O	884	894	Depression
O	895	896	(
O	896	900	CESD
O	900	901	)
O	902	907	scale
O	907	908	,
O	909	912	the
O	913	921	Hospital
O	922	929	Anxiety
O	930	933	and
O	934	944	Depression
O	945	950	Scale
O	951	952	(
O	952	956	HADS
O	956	957	)
O	957	958	,
O	959	962	the
O	963	973	Pittsburgh
O	974	979	Sleep
O	980	987	Quality
O	988	993	Index
O	994	995	(
O	995	999	PSQI
O	999	1000	)
O	1000	1001	,
O	1002	1005	the
O	1006	1009	hot
O	1010	1015	flash
O	1016	1021	daily
O	1022	1027	diary
O	1027	1028	,
O	1029	1032	the
O	1033	1036	Hot
O	1037	1042	Flash
O	1042	1043	-
O	1043	1050	Related
O	1051	1056	Daily
O	1057	1069	Interference
O	1070	1075	Scale
O	1076	1077	(
O	1077	1082	HFRDI
O	1082	1083	)
O	1083	1084	,
O	1085	1088	and
O	1089	1092	the
O	1093	1101	European
O	1102	1109	quality
O	1109	1110	-
O	1110	1112	of
O	1112	1113	-
O	1113	1117	life
O	1118	1124	survey
O	1125	1126	(
O	1126	1133	EuroQol
O	1133	1134	)
O	1135	1139	were
O	1140	1144	used
O	1145	1147	to
O	1148	1154	assess
O	1155	1159	PROs
O	1160	1162	at
O	1163	1171	baseline
O	1172	1175	and
O	1176	1178	at
O	1179	1185	4weeks
O	1185	1186	,
O	1187	1188	8
O	1189	1194	weeks
O	1194	1195	,
O	1196	1199	and
O	1200	1202	12
O	1203	1208	weeks
O	1208	1209	.

O	1210	1213	The
O	1214	1223	intention
O	1223	1224	-
O	1224	1226	to
O	1226	1227	-
O	1227	1232	treat
O	1233	1241	analysis
O	1242	1250	included
B-intervention-participants	1251	1253	23
O	1254	1262	patients
O	1263	1265	in
O	1266	1269	the
O	1270	1272	RA
O	1273	1276	arm
O	1277	1280	and
B-control-participants	1281	1283	24
O	1284	1292	patients
O	1293	1295	in
O	1296	1299	the
B-control	1300	1302	SA
O	1303	1306	arm
O	1306	1307	.

O	1308	1313	There
O	1314	1318	were
O	1319	1321	no
O	1322	1333	significant
O	1334	1345	differences
O	1346	1348	in
O	1349	1357	baseline
O	1358	1373	characteristics
O	1374	1381	between
O	1382	1385	the
O	1386	1387	2
O	1388	1394	groups
O	1394	1395	.

O	1396	1404	Compared
O	1405	1409	with
O	1410	1418	baseline
O	1418	1419	,
B-outcome	1420	1426	scores
O	1427	1429	in
O	1430	1433	the
O	1434	1436	RA
O	1437	1440	arm
O	1441	1449	improved
O	1450	1463	significantly
O	1464	1466	at
O	1467	1471	week
O	1472	1473	8
O	1474	1476	on
O	1477	1480	the
B-outcome	1481	1485	CESD
O	1486	1487	(
O	1487	1488	P
O	1489	1490	=
O	1491	1492	.
O	1492	1495	022
O	1495	1496	)
O	1496	1497	,
B-outcome	1498	1501	hot
I-outcome	1502	1507	flash
I-outcome	1508	1516	severity
O	1517	1518	(
O	1518	1519	P
O	1520	1521	=
O	1522	1523	.
O	1523	1526	006
O	1526	1527	)
O	1527	1528	,
B-outcome	1529	1532	hot
I-outcome	1533	1538	flash
I-outcome	1539	1548	frequency
O	1549	1550	(
O	1550	1551	P
O	1552	1553	=
O	1554	1555	.
O	1555	1558	011
O	1558	1559	)
O	1559	1560	,
O	1561	1564	the
B-outcome	1565	1570	HFRDI
O	1571	1572	(
O	1572	1573	P
O	1574	1575	=
O	1576	1577	.
O	1577	1580	014
O	1580	1581	)
O	1581	1582	,
O	1583	1586	and
B-outcome	1587	1592	NSABP
I-outcome	1593	1603	menopausal
I-outcome	1604	1612	symptoms
O	1613	1614	(
O	1614	1615	P
O	1616	1617	=
O	1618	1619	.
O	1619	1622	022
O	1622	1623	)
O	1623	1624	;
O	1625	1631	scores
O	1632	1634	in
O	1635	1638	the
O	1639	1641	SA
O	1642	1645	arm
O	1646	1654	improved
O	1655	1668	significantly
O	1669	1671	on
O	1672	1675	the
B-outcome	1676	1683	EuroQol
O	1684	1685	(
O	1685	1686	P
O	1687	1688	=
O	1689	1690	.
O	1690	1693	022
O	1693	1694	)
O	1694	1695	,
O	1695	1698	the
O	1699	1704	HFRDI
O	1705	1706	(
O	1706	1707	P
O	1708	1709	=
O	1710	1711	.
O	1711	1714	043
O	1714	1715	)
O	1715	1716	,
O	1717	1720	and
B-outcome	1721	1726	NSABP
I-outcome	1727	1737	menopausal
I-outcome	1738	1746	symptoms
O	1747	1748	(
O	1748	1749	P
O	1750	1751	=
O	1752	1753	.
O	1753	1756	005
O	1756	1757	)
O	1757	1758	.

O	1759	1763	Post
O	1763	1764	-
O	1764	1767	hoc
O	1768	1776	analysis
O	1777	1786	indicated
O	1787	1791	that
B-ethinicity	1792	1799	African
I-ethinicity	1800	1808	American
O	1809	1817	patients
O	1818	1819	(
O	1819	1820	n
O	1821	1822	=
O	1823	1824	9
O	1824	1825	)
O	1826	1835	benefited
O	1836	1840	more
O	1841	1845	from
O	1846	1848	RA
O	1849	1853	than
O	1854	1856	SA
O	1857	1865	compared
O	1866	1870	with
B-ethinicity	1871	1874	non
I-ethinicity	1874	1875	-
I-ethinicity	1875	1882	African
I-ethinicity	1883	1891	American
O	1892	1900	patients
O	1901	1902	(
O	1902	1903	n
O	1904	1905	=
O	1906	1908	38
O	1908	1909	)
O	1910	1912	in
O	1913	1921	reducing
B-outcome	1922	1925	hot
I-outcome	1926	1931	flash
I-outcome	1932	1940	severity
O	1941	1942	(
O	1942	1943	P
O	1944	1945	<
O	1946	1947	.
O	1947	1950	001
O	1950	1951	)
O	1952	1955	and
B-outcome	1956	1965	frequency
O	1966	1967	(
O	1967	1968	P
O	1969	1970	<
O	1971	1972	.
O	1972	1975	001
O	1975	1976	)
O	1977	1983	scores
O	1983	1984	.

O	1985	1989	Both
O	1990	1992	RA
O	1993	1996	and
O	1997	1999	SA
O	2000	2004	were
O	2005	2015	associated
O	2016	2020	with
O	2021	2032	improvement
O	2033	2035	in
O	2036	2040	PROs
O	2041	2046	among
O	2047	2055	patients
O	2056	2060	with
O	2061	2067	breast
O	2068	2074	cancer
O	2075	2078	who
O	2079	2083	were
O	2084	2093	receiving
O	2094	2097	AIs
O	2097	2098	,
O	2099	2102	and
O	2103	2105	no
O	2106	2117	significant
O	2118	2128	difference
O	2129	2132	was
O	2133	2141	detected
O	2142	2149	between
O	2150	2154	arms
O	2154	2155	.

O	2156	2162	Racial
O	2163	2174	differences
O	2175	2177	in
O	2178	2186	response
O	2187	2189	to
O	2190	2201	acupuncture
O	2202	2209	warrant
O	2210	2217	further
O	2218	2223	study
O	2223	2224	.
